Peripheral blood stem cell transplantation: Approaches to an optimal blood stem cell collection

Coffe, C; Couteret, Y.; Devillers, M.; Fest, Thierry; Morel, Pierre; Pouthier-Stein, F.; Calot, J.P.; Novakovitch, G; Sitthy, X; Tremisi, P.J.

doi:10.1016/0955-3886(92)90023-a

Cited by 8 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A newly developed, fully automatic cell separator AS 104 (Fresenius Co., Oberursel, Germany) is useful for the collection of PBSC (4)(5)(6)(7). However, we were not able to collect adequate grafts from CML patients with high numbers of platelets because these platelets formed a thick layer that interfered with the red cell interface sensor of the machine.…”

Section: Introductionmentioning

confidence: 96%

Technical Report: Efficient Collection of Peripheral Blood Stem Cells Using the Fresenius AS104 in Chronic Myelocytic Leukemia Patients with Very High Numbers of Platelets

Komatsu¹,

Ishida²

1997

Journal of Hematotherapy

View full text Add to dashboard Cite

For chronic myelocytic leukemia patients with very high numbers of platelets, we describe an efficient method for the collection of peripheral blood stem cells (PBSC) using the Fresenius AS104 cell separator. In these patients, it is difficult to collect a sufficient number of PBSC, due to the platelet band interfering with the machine's red cell interface sensor. We, therefore, tried a manual adjustment of the device. The collection phase was set automatically. When the whole blood began to separate into the red cell layer and plasma (plus mononuclear cell) layer, the red cell interface setting of "7:1" was changed to "OFF," and the plasma pump flow rate was controlled manually in order to locate the interface position 1 cm from the outside wall of the centrifuge chamber. After the collection phase, the procedure was returned to the automatic setting. By repeating this procedure, we were able to collect large numbers of PBSC.

show abstract

Section: Introductionmentioning

confidence: 96%

Technical Report: Efficient Collection of Peripheral Blood Stem Cells Using the Fresenius AS104 in Chronic Myelocytic Leukemia Patients with Very High Numbers of Platelets

Komatsu¹,

Ishida²

1997

Journal of Hematotherapy

View full text Add to dashboard Cite

show abstract

“…In recent years, autologous PBSC transplantation has been described as a procedure with some advantages over autologous bone marrow transplantation after ablative che motherapy or radiotherapy [1]. Probably, there are two fac tors which condition a good recovery after autologous PBSC transplantation: the number and the quality of the cells collected.…”

Section: Platelet and Red Cell Contaminationmentioning

confidence: 99%

“…In the last few years, re-infusion of autologous periph eral blood stem cells (PBSCs) has been used as an alterna tive procedure to obtain bone marrow reconstitution after ablative chemotherapy [1], Some investigators have found Cell numbers expressed in cells x 10'Vl. MM = Multiple myeloma; HD = Hodgkin's disease; NHL = non-Hodgkin's lymphoma; PR = partial remission; CR = complete remission.…”

Section: Introductionmentioning

confidence: 99%

Circulating Stem Cell Collection in Lymphoma and Myeloma after Mobilization with Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Autologous Transplantation

Cancelas¹,

Hernández-Jodra²,

Zamora³

et al. 1994

Vox Sanguinis

View full text Add to dashboard Cite

We report the results of 72 leukapheresis procedures performed for autologous peripheral blood stem cell collection in 18 patients with lymphoma and myeloma, after combined mobilization with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF). The numbers of mononuclear cells (MNCs), CD34+ cells and granulocyte-macrophage colony-forming units (CFU-GM) either in the peripheral circulation (preleukapheresis sample) or in the product obtained from leukapheresis (leukapheresis sample) were evaluated. A highly superior proportion of CD34+ cells (14-fold) and CFU-GM (5-fold) resulted from the mobilization therapy. CFU-GM and CD34+ cells were highly enriched with respect to all MNCs (relative recoveries: 2.13, range 0.3—41, and 1.08, range 0.2- 8.5, respectively) due to an additional mobilization effect by the leukapheresis procedure. Also, a relatively strong linear correlation between the three different parameters was found in the leukapheresis product (CD34+:CFU-GM, r = 0.81; MNCs:CD34, r = 0.69; MNCs:CFU-GM, r = 0.75; CFU-GM:CD34+, and MNCs, r = 0.85). Our data suggest that the number of MNCs and CD34+ cells obtained after combined mobilization with cyclophosphamide and G-CSF can be used as predictor of the number of granulomonocytic progenitors.

show abstract

“…Fever, occurring in all patients and lasting 3 to 9 days, and I-II WHO mucositis, occurring in eight patients, were the only early complications. All patients reached myeloid engraftment at 13 days (range, [11][12][13][14][15][16] and platelet engraftment at 27 days (range, 13-49) after infusion, with no need for any back-up infusion. At a median time of 9 days (range, 12-34), nine patients developed an 'engraftment syndrome', consisting of diffuse skin erythema, possibly associated with fever, 25 which required treatment with steroids for a median of 26 days (range, 9-47).…”

Section: Post-transplant Follow-upmentioning

confidence: 99%

“…Once a threshold of 0.05 × 10 9 CD34 + cells/l was reached, the leukapheresis was performed through a central venous catheter and a temporary peripheral vein access, by means of a continuous flow cell separator (COBE Spectra, Lakewood, CO, USA), and approximately 2.5 patient-blood volumes were processed to obtain at least 5 × 10 6 CD34 + cell/kg; if necessary, a second leukapheresis was performed the following day. 13 In order to prevent clotting, ACD was used at a ratio of 1:12 for children weighing 25 kg or more; for children under 25 kg, 1:16 ACD combined with heparin 50 U/kg was used, and the separator was initialized with a compatible filtered and irradiated RBC unit, suspended in albumin, up to the patient's hematocrit, to avoid transient hypovolemia, due to the volume sequestered in the separator.…”

Section: Mobilization and Collectionmentioning

confidence: 99%

Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions

et al. 2001

View full text Add to dashboard Cite

Autologous transplantation is a treatment option for relapsed childhood acute lymphoblastic leukemia (ALL) in second complete remission (CR2) when a suitable donor is not available. In an attempt to prevent relapses originating from graft leukemic contamination, the experimental protocol of in vitro purification of leukapheretic products with monoclonal antibodies (MoAbs), previously reported for adults, was adopted in 11 of 12 consecutive patients (median age, 9 years) with B cell precursor ALL in CR2 after late relapse (median, 37; range, 31-51 months after the onset) enrolled between July 1997 and July 1999 at a single pediatric center. At a median of 12 days after the mobilizing chemotherapy followed by G-CSF, a median of 13.9 (range, 5.9-18.7) × 10 6 CD34 + cells/kg were collected from each patient and a median of 7.5 (range, 4.1-12.6) × 10 6 CD34 + cells/kg underwent the purification procedure. The first step of immunorosetting allowed a one-log reduction of the total cell count, by eliminating more than 90% of the CD11b

show abstract

Peripheral blood stem cell transplantation: Approaches to an optimal blood stem cell collection

Cited by 8 publications

References 42 publications

Technical Report: Efficient Collection of Peripheral Blood Stem Cells Using the Fresenius AS104 in Chronic Myelocytic Leukemia Patients with Very High Numbers of Platelets

Technical Report: Efficient Collection of Peripheral Blood Stem Cells Using the Fresenius AS104 in Chronic Myelocytic Leukemia Patients with Very High Numbers of Platelets

Circulating Stem Cell Collection in Lymphoma and Myeloma after Mobilization with Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Autologous Transplantation

Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions

Contact Info

Product

Resources

About